Abstract
Liver cancer is the fifth most common cancer in worldwide cancer mortalities. The present study was undertaken to evaluate the anticancer properties of two edible bivalve species Meretrix meretrix and eretrix. casta on human hepatoma cell line HepG2. The anticancer properties of bivalves have been evaluated by using the Trypan blue exclusion assay, lactate dehydrogenase activity (LDH), caspase 3 activity, glutathione level (GSH) and DNA fragmentation assay. Both mollusc extracts M. meretrix extract (MME) and M. casta extract (MCE) treated HepG2 cells showed significant inhibition of cell viability at (IC50) 50 µg/ml concentration in the trypan blue exclusion assay. With light microscopic observation the extract treated HepG2 cells showed modified cell morphological features. Lactate dehydrogenase was significantly released from the extracts treated cells. Reduced glutathione levels were observed in MME and MCE treated HepG2 cells. Further DNA ladder assay showed a fragmented laddering pattern of DNA in molluscan extracts treated cells, it further confirms the induction of apoptosis in HepG2 treated cells. As compared to MME, the MCE showed weaker anticancer property. On observation, it can be concluded that extract MME has been a highly selective and effective anticancer drug for human welfare. Key words: Meretrix meretrix, Meretrix casta, trypan blue exclusion assay, lactate dehydrogenase (LDH) assay, caspase 3, DNA ladder assay
Highlights
Liver cancer or hepatocellular carcinoma (HCC) was one of the leading causes of worldwide cancer mortality (ElSerag and Mason, 1999)
Reduced glutathione levels were observed in M. meretrix extract (MME) and M. casta extract (MCE) treated HepG2 cells
It can be concluded that extract MME has been a highly selective and effective anticancer drug for human welfare
Summary
Liver cancer or hepatocellular carcinoma (HCC) was one of the leading causes of worldwide cancer mortality (ElSerag and Mason, 1999). The endemic mortalities of HCC were observed in tropical and subtropical countries. The major risk factors involved in HCC were viral particle. Hepatitis B and some hepatocarcinogens such as nitrosamines, aflatoxins etc. The therapeutic options are surgical interventions (tumor resection and liver transplantation), radiation therapy, chemotherapy, immune therapies. These therapeutic methods are producing adverse side effects. It is necessary to evaluate the new active drugs against HCC with the lack of side effects from a cheaper source
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
